Last week, Humana announced it is exiting Medicare Advantage markets serving approximately 600,000 members in 2027. The announcement was framed as a business decision around profitability pressures in the MA space. The 600,000 members were not part of the framing.
I want to talk about what happens to them. When a plan exits a market, the clinical picture gets complicated quickly, and it does not get complicated in a way that shows up cleanly on a quarterly slide.
MA plans tend to enroll older, higher-complexity patients who chose them specifically for benefits original Medicare does not offer: dental, vision, transportation, home modification. These are patients on multiple medications, often with active care management relationships. Some are in disease management programs the plan administers. Some have a care coordinator they have spoken with every month for two years.
When the plan exits, those relationships end. The care coordinator is gone. The supplemental benefits stop. The formulary changes. The network changes.
"A patient who has been stable for 18 months can become a new clinical problem inside a six-week coverage transition."
Coverage transitions drive acute care volume. This is not a hypothesis. It is a pattern that repeats across every significant MA market exit I have seen data on. Patients delay filling prescriptions while they wait to understand what the new plan will cover. They miss follow-up appointments because they do not know if the specialist is in network. They hold off calling the primary care office because they are not sure who their primary care doctor is anymore.
Then something tips, and they present acutely.
Whoever picks them up has no context for why this particular patient, well-managed for the past year, is now presenting with a blood sugar that has not been this high since before the GLP-1 started. The connection to the coverage transition is invisible unless someone asks the right question and has the time to ask it.
Identify the at-risk population now. Your payer mix data can surface which patients currently carry Humana MA coverage in the affected markets. That is your cohort for proactive outreach.
Build a formulary watch list. GLP-1s, specialty drugs, high-cost injectables: these are the categories where a 30-day formulary gap causes the fastest clinical deterioration. Flag those patients for proactive follow-up during the transition window.
The deeper question is where these 600,000 members land after the exit. Some will find comparable MA plans. Others will disenroll to original Medicare, apply for Medicaid if income permits, or fall into coverage gaps for months while navigating the comparison tools. Each path carries a different reimbursement rate for the health system that sees them next.
Your 2027 financial model should be stress-testing that spread now, not after the volume hits.
I want to be direct about something: the clinical response to a patient in front of you should not vary based on what their coverage looks like when they arrive. It does not, in most systems. The operational and financial planning that supports that care, however, has to account for the revenue per encounter change, or the impact arrives in the second half of 2027 without preparation.
Health systems that serve large MA populations need to be running two tracks simultaneously: a patient-facing proactive outreach track aimed at minimizing care disruption, and an internal financial modeling track aimed at understanding what the payer mix shift looks like across the range of landing scenarios.
These are not competing priorities. The systems that run both tracks will be in a better position on both the clinical and the financial side.
The 600,000 figure is going to become a policy footnote and a business story: a profitability problem at a major insurer, a market exit, a strategic pivot toward commercial lines.
At the care delivery level, it is 600,000 patients who have a health plan today and will not have the same one in 2027. Some of them have chronic conditions that are currently well-controlled. Some have never had to think about what a coverage transition means for their medication list, their specialist relationship, or their care coordinator.
The patients who will navigate this most smoothly are the ones with the fewest health needs, the strongest health literacy, and the most time to compare plans.
The ones who will show up in your emergency department are not those patients.
I am a surgery-trained physician-executive currently practicing internal medicine (charity care), with experience building clinical strategy and governance frameworks during the Cerner acquisition at Oracle Health. I advise health systems on clinical AI strategy, payer transitions, and implementation. For a 20-minute scoping conversation: calendly.com/sarahmattmd
If a payer exit is coming to your markets, the cohort work and the financial stress test both belong in this year's plan. I build that view with leadership teams in four to six weeks.